Klinische Erfahrungen mit Methylperon (Buronil®), einem neuen Butyrophenonderivat

Publisher Website
Google Scholar
Abstract
Methylperone is a new major tranquilizer of the benzophenone series. With a moderately broad therapeutic spectrum, it presents a good antipsychotic effect, especially on acute exacerbations and cases of schizophrenia of recent onset. Oral and parenteral therapy are of equal value, so that the former is preferable on account of the fewer side-effects. Marked sedation is obtained only with high doses. The main side-effects consist of hyperkinetic and hypertonic parkinsonian symptoms, which are easily controlled by the usual antiparkinson remedies. The latter should also be given by mouth, because of the danger of drug-induced delirium. Experience with 104 male schizophrenics in the psychiatric hospital in Vienna have shown that methylperone, after initial treatment in hospital and appropriate adjustment of the dosage, is most suitable for continued use on an out-patient basis and for long-term therapy.

This publication has 0 references indexed in Scilit: